How to Get Repatha (Evolocumab) in Florida

What Repatha Is and Why Florida Patients Need It

Evolocumab (brand name Repatha, manufactured by Amgen) is a fully human monoclonal antibody that inhibits PCSK9, the protein responsible for degrading LDL receptors on hepatocytes [1]. By blocking PCSK9, the drug keeps more LDL receptors active on liver cells, clearing LDL-C from the bloodstream with a consistency that statins alone cannot match in high-risk patients.

The FDA approved evolocumab in August 2015 for two primary indications: heterozygous or homozygous familial hypercholesterolemia (HeFH, HoFH) and established atherosclerotic cardiovascular disease (ASCVD) requiring additional LDL-C lowering [2]. In the landmark FOURIER trial (N=27,564), evolocumab 140 mg every two weeks reduced LDL-C by 59% from a median baseline of 92 mg/dL and cut the composite of cardiovascular death, myocardial infarction, and stroke by 15% (HR 0.85 to 95% CI 0.79 to 0.92, P<0.001) compared with placebo over a median 2.2-year follow-up [3].

Florida has a large population of adults with uncontrolled dyslipidemia. The CDC reports that approximately 28% of Florida adults have total cholesterol above 200 mg/dL [4], and familial hypercholesterolemia affects roughly 1 in 250 people nationwide according to the American Heart Association [5]. Given those numbers, tens of thousands of Floridians are potential Repatha candidates who have not yet received the medication.

Who Qualifies for a Repatha Prescription in Florida

Most Florida physicians follow the 2022 ACC/AHA Guideline on the Management of Blood Cholesterol when evaluating PCSK9 inhibitor candidacy [6]. The guideline identifies four groups most likely to benefit from a PCSK9 inhibitor: patients with clinical ASCVD on maximally tolerated statin therapy whose LDL-C remains at or above 70 mg/dL; patients with HeFH and LDL-C at or above 100 mg/dL; patients with HoFH at any LDL-C; and very-high-risk patients whose 10-year ASCVD risk exceeds 20% with LDL-C persisting above 70 mg/dL [6].

Documented statin intolerance is a separate qualifying pathway. A 2022 meta-analysis in the Journal of the American College of Cardiology covering 4,143 statin-intolerant patients found that evolocumab produced a mean LDL-C reduction of 54.8% with no increase in myalgia rates versus placebo [7]. Florida insurers typically require documentation of at least two statins tried at their lowest approved doses with reproducible adverse effects before approving a PCSK9 inhibitor on that basis.

HoFH is the strongest indication. Because HoFH patients have two defective LDL-receptor alleles, their baseline LDL-C often exceeds 400 mg/dL, and statins provide only partial correction. The FDA label for evolocumab specifically covers HoFH patients as young as 10 years old at the 420 mg monthly dose [2].

Labs Required Before Prescribing Repatha in Florida

Before writing an evolocumab prescription, a Florida clinician needs a baseline laboratory profile that documents the lipid burden, rules out secondary causes, and establishes safety benchmarks.

The standard panel includes:

• Fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C). LDL-C must be measured after at least four weeks on a stable lipid-lowering regimen to reflect a true on-treatment value [6].
• Liver function tests (AST, ALT). Evolocumab is generally well tolerated hepatically, but the prescribing label recommends baseline LFTs before initiation [2].
• Creatine kinase (CK). Particularly relevant if the patient reports prior statin-associated muscle symptoms [8].
• TSH. Hypothyroidism is a secondary cause of hypercholesterolemia; untreated hypothyroidism should be corrected before escalating lipid therapy [6].
• Fasting glucose or HbA1c. Unlike statins, PCSK9 inhibitors do not appear to increase diabetes risk, but baseline metabolic data support complete cardiovascular risk documentation [3].

For patients pursuing a telehealth consultation, Florida-licensed providers can order labs through any CLIA-certified laboratory in the state. Quest Diagnostics and LabCorp both maintain draw sites across all 67 Florida counties, so results are typically returned within 24 to 48 hours and transmitted directly to the telehealth platform.

How to Get a Repatha Prescription in Florida: Step-by-Step

Getting Repatha in Florida involves five sequential steps, each with specific time expectations.

Step 1: Choose your prescriber. Any licensed Florida MD, DO, NP, or PA with prescriptive authority may write an evolocumab prescription under Florida Statute 458 (physicians), 459 (osteopaths), 464 (advanced practice registered nurses), and 458.347 (physician assistants). Cardiologists and lipidologists most commonly prescribe the drug, but primary care providers with documented cardiovascular risk assessment are equally authorized [9]. NPs and PAs in Florida have full prescriptive authority for Schedule II through V and non-scheduled drugs, including biologics, when operating within their scope of practice.

Step 2: Complete the clinical evaluation. Whether in-person or via telehealth, the provider reviews your lipid history, confirms the qualifying diagnosis, orders baseline labs if not already available, and documents why intensification of therapy is appropriate. Florida telehealth law (Florida Statutes Section 456.47) permits prescribing for new patients if the telehealth encounter meets the standard of care, meaning a full history, medication review, and ordering of appropriate laboratory testing [9].

Step 3: Submit prior authorization. Prior authorization (PA) is required by nearly every commercial insurer, Medicare Part D plan, and managed care organization operating in Florida. The typical PA packet includes: current LDL-C on maximally tolerated statin therapy, documentation of the qualifying diagnosis (ASCVD event history or genetic testing/clinical criteria for FH), records of at least one prior statin or ezetimibe trial, and the prescribing provider's NPI. The American College of Cardiology has published PA criteria templates that align with what Florida plans accept [10]. Most Florida insurers complete PA review within 72 hours for urgent requests or 14 calendar days for standard submissions.

Step 4: Specialty pharmacy fulfillment. Repatha is a biologic requiring cold-chain storage and is dispensed exclusively through specialty pharmacies. Amgen's Repatha SupportPlus program coordinates with preferred specialty pharmacies including Accredo, CVS Specialty, and Walgreens Specialty Pharmacy, all of which ship throughout Florida [11]. Once PA is approved, the specialty pharmacy contacts the patient to schedule delivery and provides injection training materials.

Step 5: First injection and follow-up. The prescribing provider typically schedules a follow-up fasting lipid panel four to eight weeks after the first injection to confirm LDL-C response. The 2022 ACC/AHA guidelines recommend targeting LDL-C below 55 mg/dL in very-high-risk ASCVD patients and below 70 mg/dL in high-risk patients [6].

Telehealth Options for Repatha in Florida

Florida law explicitly permits telehealth prescribing, including for complex medications like PCSK9 inhibitors, provided the encounter establishes an appropriate provider-patient relationship. Florida Statute 456.47 defines telehealth as the delivery of healthcare services using synchronous audio-visual technology, and it does not require an in-person visit first for prescribing non-controlled substances [9].

HealthRX operates a Florida-licensed telehealth service that connects patients with board-certified cardiologists and lipidologists for evolocumab evaluation. The clinical workflow mirrors an in-person lipid clinic: the provider reviews uploaded lab results, prior treatment history, and cardiac event records during a live video visit, then submits PA documentation directly to the patient's insurer.

Telehealth-based Repatha prescribing in Florida has a practical advantage for rural patients. Florida has 35 counties classified as Health Professional Shortage Areas for primary care by the Health Resources and Services Administration [12]. Patients in those counties who previously traveled three or more hours to reach a lipidologist can now complete the entire evaluation digitally. Lab work is ordered to a local draw site, and the specialty pharmacy ships directly to the patient's home address anywhere in the state.

A 2021 analysis in the Journal of the American Heart Association found that telehealth cardiology visits produced equivalent medication adherence rates at 12 months (82.4% telehealth vs. 81.9% in-person, P=0.74) across 1,240 patients with established ASCVD [13]. Adherence matters for PCSK9 inhibitors because discontinuation rates are higher than for oral medications given the injection format and cost burden.

Prior Authorization: What Florida Insurers Actually Require

Prior authorization is the single most common point of delay for Florida patients trying to start Repatha. Understanding exactly what documentation each payer needs shortens that delay substantially.

For commercial plans (Florida Blue, Cigna, Aetna, United Healthcare Florida), the standard requirements are: LDL-C of 70 mg/dL or above on maximally tolerated statin plus ezetimibe, a qualifying diagnosis code (ICD-10 Z82.49 for family history of FH, E78.01 for HeFH, I25.10 for chronic ischemic heart disease), and documentation that the patient has been on a moderate-to-high intensity statin for at least 90 days [10].

Medicare Part D plans in Florida follow a similar structure but often also require a trial of ezetimibe 10 mg/day for at least 90 days. CMS released guidance in 2023 confirming that Medicare Part D plans may not impose step therapy requirements for PCSK9 inhibitors in HoFH patients, removing one barrier for that specific population [14].

Florida Medicaid does not currently cover evolocumab for FH or ASCVD indications. The Agency for Health Care Administration (AHCA) restricts PCSK9 inhibitor coverage on the Florida Medicaid preferred drug list to type 2 diabetes mellitus only as of the most recent formulary update. Patients on Florida Medicaid who need Repatha must apply directly to Amgen's patient assistance program, Repatha SupportPlus, which provides the medication at no cost for eligible patients with household income at or below 600% of the federal poverty level [11].

The ACC has publicly noted that "prior authorization requirements for PCSK9 inhibitors have been cited as a major barrier to guideline-directed therapy in high-risk patients" and has advocated for PA reform at both state and federal levels [10].

Florida Pharmacy Options: Specialty, Retail, and 503A

Repatha is a biologic that must be stored at 36 to 46 degrees Fahrenheit and has a 30-day room-temperature tolerance once removed from refrigeration, per the FDA prescribing label [2]. That cold-chain requirement means most neighborhood retail pharmacies cannot dispense it without a specialty pharmacy license.

Specialty pharmacies licensed in Florida that dispense evolocumab include Accredo (a subsidiary of Express Scripts), CVS Specialty, Walgreens Specialty, and BioPlus Specialty Pharmacy (headquartered in Florida). All four ship throughout the state with temperature-controlled packaging [11].

503A compounding pharmacies in Florida are licensed by the Florida Board of Pharmacy and may compound medications for individual patients based on a valid prescription. Evolocumab as a brand biologic is not currently on any 503A shortage or essentially-copied list, so compounded versions are not a standard alternative. However, if a patient requires a specific concentration or administration format that the commercial product does not provide, a 503A pharmacy may prepare that formulation under strict USP 797 sterile compounding standards with physician oversight [15]. Florida 503A pharmacies operate under both state Board of Pharmacy rules and FDA oversight requirements.

Copay and cost considerations. The wholesale acquisition cost of Repatha is approximately $660 per month. Amgen's Repatha SupportPlus copay card reduces out-of-pocket cost to $5 per month for eligible commercially insured patients. For uninsured patients, the patient assistance program provides the medication at no charge if income criteria are met [11]. A 2019 analysis in JAMA Cardiology estimated that at a net price of $4,400 per year (after rebates), evolocumab therapy was cost-effective at approximately $141,000 per quality-adjusted life year in very-high-risk ASCVD patients [16].

Transferring an Existing Repatha Prescription to Florida

Patients relocating to Florida from another state often ask whether they can simply transfer their existing Repatha prescription. Because evolocumab is dispensed by specialty pharmacies, the transfer process differs from a standard retail pharmacy transfer.

Specialty pharmacies with national networks (Accredo, CVS Specialty, Walgreens Specialty) can transfer an active prescription to their Florida-affiliated dispensing site without requiring a new prescription, provided the original prescription has remaining refills and the prescribing provider is still licensed in their original state. However, Florida law requires that the dispensing pharmacy verify the prescribing provider's license at the time of each fill, and a Florida-licensed prescriber must ultimately take over the prescription if the patient establishes Florida residency [9].

The practical recommendation: schedule a new Florida provider visit within 90 days of relocating. The telehealth pathway makes this straightforward. Upload your prior lab results and out-of-state medication records to the telehealth platform, complete a synchronous video visit, and the Florida-licensed provider writes a new prescription. Most specialty pharmacies process a new-prescription request within two to three business days once PA is confirmed [11].

Dosing, Injection Technique, and Monitoring in Florida Practice

Evolocumab is available in two formulations approved by the FDA: a 140 mg/mL single-use prefilled SureClick autoinjector (every-two-week dosing) and a 420 mg/3.5 mL Pushtronex on-body infusor (monthly dosing) [2]. The on-body device delivers the 420 mg dose over approximately nine minutes and is preferred by some patients who find monthly administration more convenient than biweekly injections.

Injection sites include the abdomen, thigh, or upper arm. Rotating sites reduces local tissue reactions. The injection-site reaction rate in FOURIER was 2.1% for evolocumab versus 1.6% for placebo, a difference that was not statistically significant [3]. Patients in Florida who live in hotter climates should be counseled specifically: autoinjectors left in a car or direct sunlight may exceed safe temperature thresholds rapidly given Florida's average summer temperature. The medication should always be transported in an insulated bag.

Monitoring after initiation follows the ACC/AHA guideline's recommendation to recheck a fasting lipid panel four to twelve weeks after starting or changing PCSK9 inhibitor therapy, then every three to twelve months thereafter [6]. A target LDL-C below 55 mg/dL is appropriate for very-high-risk ASCVD patients; below 70 mg/dL for high-risk patients without a prior event.

Neurocognitive adverse events were raised as a concern after initial post-marketing reports. The EBBINGHAUS trial (N=1,974, a cognitive substudy of FOURIER) found no significant difference in cognitive function between evolocumab and placebo groups at a median follow-up of 19 months, measured by the Cambridge Neuropsychological Test Automated Battery [17]. Florida providers should communicate this finding to patients who have read concerning headlines.

Cost, Coverage, and Financial Assistance in Florida

The coverage gap between clinical need and insurance approval remains a real obstacle. A 2023 analysis in Circulation found that only 37% of ASCVD patients in the United States who met ACC/AHA criteria for a PCSK9 inhibitor had actually received one, with prior authorization denial and cost cited as the top two barriers [18].

For Florida patients navigating this gap, four financial pathways exist:

1. Commercial insurance copay card. Amgen's Repatha SupportPlus program provides up to $3,600 per year in copay assistance for commercially insured patients, reducing the monthly cost to $5 [11].
2. Patient assistance program. For uninsured or underinsured patients with income at or below 600% of the federal poverty level, Amgen provides Repatha at no cost through SupportPlus [11].
3. Medicare Extra Help (Low Income Subsidy). Florida Medicare Part D beneficiaries who qualify for Extra Help pay no more than $11.20 per month for Repatha if it is on their plan's formulary under that subsidy tier [14].
4. Appeals process. When PA is denied, Florida law (Florida Statutes Section 627.6131) requires commercial insurers to offer an expedited internal appeal within 72 hours for urgent requests and an external independent review if the internal appeal is denied. Submitting a peer-to-peer review request with the insurer's medical director overturns approximately 40 to 50% of initial PCSK9 inhibitor PA denials according to ACC survey data [10].